ArticleBioactive materials2026
Application of IFN-γ-Licensed urine-derived stem cells in SIS hydrogel promotes scar-free wound healing by immunomodulation and microenvironment remodeling.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements in Functional Polymeric Scaffolds for Scar-Free Skin Regeneration.Polymer science & technology (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scar-free wound healing remains an unmet clinical imperative, as dysregulated immune microenvironment during tissue repair drives irreversible fibrosis. While existing treatments (corticosteroid injections, laser therapy, surgical excision) provide symptomatic relief, they fail to address the pathophysiological triad of fibrosis: persistent fibroblast activation, aberrant ECM deposition, and chronic inflammation. Mesenchymal stem cell (MSC) therapy has emerged as a promising strategy to concurrently target these pathological axes. Among MSC sources, urine-derived stem cells (USCs) stand out as a superior candidate, owing to their non-invasive accessibility, minimal ethical concerns, favorable safety profile, and robust proliferative capacity. In this study, we explored the therapeutic potential of IFN-γ-pretreated urine-derived stem cells (γ-USCs) encapsulated in small intestinal submucosa (SIS) hydrogel for scar-free skin wound healing. Our findings demonstrated that IFN-γ pretreatment potentiated the immunomodulatory properties of USCs, driving macrophage polarization toward an anti-inflammatory phenotype to normalize the wound microenvironment. In vitro, γ-USCs significantly suppressed the hyperactivity of keloid fibroblasts and attenuated TGF-β-induced fibrotic responses, as evidenced by reduced collagen deposition and downregulated fibrotic markers. In vivo, using a rabbit ear scar model, SIS hydrogel-encapsulated γ-USCs (γ-USCs@SIS) markedly alleviated scar formation, with histopathological analyses revealing improved tissue architecture, balanced collagen remodeling, and restored skin biological function. Collectively, the γ-USCs@SIS system synergizes the enhanced immunomodulatory capacity of IFN-γ-pretreated USCs with the supportive microenvironment provided by SIS hydrogel, offering an innovative and translatable strategy for scar-free wound healing. This approach holds significant potential to advance fibrosis treatment by addressing the root causes of pathological scarring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.